Risk for cervical cancer increased in current users of hormonal contraception but declined after use stopped.
Cervical cancer risk is increased in current and recent users of hormonal contraception, but the effect’s duration has not been delineated. To quantitate this risk more precisely, investigators pooled data on 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 studies. Analyses were stratified by potential confounders (e.g., study site, time since last use, and type of contraceptive [oral or injectable; combined oral estrogen-progestogen or progestogen only]).
The risk for cervical cancer was higher in current users of combined oral contraceptives than in never users (relative risk, 1.9 with more than 5 years’ use). After cessation of use, the risk declined, equaling that of never users in 10 years. The increas…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)